FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued Oral DTG/ABC/3TC at Wk 96

March 8-11, 2020; Boston, Massachusetts
Switch to monthly injections of long-acting cabotegravir + rilpivirine after 20-week induction with oral 3-drug ART in treatment-naive patients noninferior to continued oral 3-drug ART for the maintenance of virologic suppression at Week 96 and demonstrates higher patient-reported satisfaction.
Format: Microsoft PowerPoint (.ppt)
File Size: 253 KB
Released: March 11, 2020


Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Limited treatment-emergent capsid resistance occurred after 28 weeks of treatment with oral or subcutaneous lenacapavir plus FTC/TAF from ID Week 2021 reported by Clinical Care Options (CCO)

Released: October 5, 2021

Switch to DTG/3TC shows high levels of efficacy, favorable safety and tolerability, and high barrier to resistance through 3 years from IDWeek 2021 presented by Clinical Care Options (CCO)

Released: October 5, 2021

Diapositivas descargables creadas por expertos que analizan los desarrollos clínicos más importantes en el manejo del VIH desde el año pasado

Babafemi Taiwo, MBBS
Program Director
Rajesh T. Gandhi, MD Daniel R. Kuritzkes, MD Darcy Wooten, MD
Released: October 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.